Mode
Text Size
Log in / Sign up
Phase 3 N=78 Randomized Quadruple-blind Treatment

4-drug Nerve Block Versus Plain Local Anesthetic for Knee and Hip Arthroplasty Analgesia in Veterans

Pain

Enrolled (actual)
78
Serious AEs
0.0%
Results posted
Dec 2021
Primary outcome: Primary: Short-Form McGill Pain Questionnaire (Version 2) Total Score Difference From Baseline — -1.85; -0.05 score on a scale — p=0.003

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Bupivacaine + CBD (clonidine, buprenorphine, dexamethasone) (Drug); Bupivacaine Only (control arm) (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Brian Williams
Primary completion
Jul 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Short-Form McGill Pain Questionnaire (Version 2) Total Score Difference From Baseline
-1.85; -0.05 0.003 sig
PRIMARY
SF-MPQ2 Continuous Pain Subscore Difference From Baseline
-2.29; 0.33 0.001 sig
PRIMARY
SF-MPQ2 Intermittent Pain Subscore Difference From Baseline
-2.79; -1.14 0.038 sig
SECONDARY
Quality of Recovery 15 Item Scale (QoR-15) Total Score
128.89; 130.06 0.861
SECONDARY
Quality of Recovery 15 Item Scale (QoR-15) Total Score
128.89; 130.06 0.861
SECONDARY
Performed-based Physical Function is Assessed Using the Standing Balance Test.
3.86; 3.94 0.512
SECONDARY
Performed-based Physical Function is Assessed Using the Self-Selected Gait Speed Test.
0.88; 0.94 0.339
SECONDARY
Performed-based Physical Function is Assessed Using the Repeated Chair Stand Test.
12.34; 11.93 0.711

Summary

After total joint replacement, early hospital discharge to home (with patients capable of continuing a home-based rehabilitation program) is a cost- effective management strategy. This project will use improved local anesthetic nerve block techniques to enhance technical capability and clinical practice by (i) reducing pain and other morbidities during recovery, (ii) improving weight-bearing achievement during in-hospital physical therapy to allow for earlier return home, and (iii) continued rehabilitation as an outpatient at home when feasible (versus in an extended care facility).

Eligibility Criteria

Inclusion Criteria

  • Age between 18 and 85, and undergoing a total knee or hip replacement.
  • Fluent in English, decision competent, willing and able to provide written informed consent, and able to complete the study's schedule of assessments.
  • Able to walk >3m without an assisting device.
  • Have a BMI ≤ 40 kg/m2.

Exclusion Criteria

  • Current participation in another orthopedic/Physical Therapy/rehab/anesthesiology interventional clinical trial.
  • Are at significant behavioral risks or have refractory major psychiatric disorders.
  • Revision surgery on the same extremity.
  • Have an American Surgical Association (ASA) Physical Status classification of 4 or higher.
  • Have been diagnosed with clinically significant neuropathy with its origins in either diabetes or other causes; have neuromuscular disease that would influence data collection.
  • Have a surgically-fused lumbar spine, or a spinal cord simulator, or other condition that would contraindicate or prohibit the conduct of spinal anesthesia.
  • At significant risk for postoperative substance abuse, or immediate-postoperative substance abuse withdrawal symptoms (alcohol, cocaine, enrolled in methadone or buprenorphine opioid withdrawal programs, etc.) Previous or current use of marijuana will not be an exclusion for study enrollment.
  • Are undergoing Total Knee Arthroplasty (TKA)/Total Hip Arthroplasty (THA) for a tumor.
  • Have contraindications (e.g., anaphylaxis) to any of the study drugs.
  • Have a systemic fungal infection.
  • Have a known hypersensitivity to bupivacaine hydrochloride or to any local anesthetic of the amide-type or to other components of bupivacaine hydrochloride solutions.
  • Have a known or suspected buprenorphine hypersensitivity (not including nausea and/or vomiting).
  • Have a gastro-intestinal (GI) obstruction.
  • Have paralytic ileus.
  • Pregnant women
  • Have had a kidney or liver transplant.

Veterans will not be excluded from participation based on smoking status, diagnosis of obstructive sleep apnea, or baseline monitored consumption of therapeutic opioids for documented medical indications; instead, these variables will be codified and quantified for subsequent covariate statistical analysis.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02891798). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search